Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Bladder Cancer
•
Medical Oncology
Under what circumstances would it be appropriate to offer trimodality therapy (TMT) in muscle-invasive bladder cancer with localized variant histology?
Related Questions
Based on the results of the BladderPath trial, are you considering multiparametric bladder MRI for all patients with suspected bladder cancer diagnosis prior to TURBT, or for select patients only?
How do you manage dysgeusia from Enfortumab Vedotin?
Would you recommend patients with newly diagnosed bladder cancer to discontinue SGLT2 inhibitors?
What is the optimal approach to systemic therapy for metastatic squamous cell carcinoma of the bladder considering the approval of enfortumab vedotin plus pembrolizumab for metastatic urothelial carcinoma?
What are your top takeaways in GU Cancers from ESMO 2024?
How do you manage enfortumab vedotin related DKA that is refractory to standard therapy (insulin, fluids, etc)?
How would you approach adjuvant therapy in MIBC with predominantly squamous cell differentiation?
In patients with localized small cell bladder cancer, would you consider consolidation with durvalumab after neoadjuvant chemotherapy followed by definitive local therapy (cystectomy or RT)?
Would you give immunotherapy after neoadjuvant gem-cis for bladder cancer if cystectomy is being postponed for months due to non-autoimmune/unrelated comorbidities?
How do you decide between internal versus external decompression of malignant obstruction of the ureter (MUO)?
